The cell cycle and how it is steered by Kaposi's sarcoma-associated herpesvirus cyclin

Emmy W. Verschuren1, Nic Jones2 and Gerard I. Evan3

1 Stanford University, Pathology Department, 300 Pasteur Drive, MC 5324, Stanford, CA 94305, USA
2 Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Manchester M20 4BX, UK
3 Cancer Research Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, CA 94143-0875, USA

Correspondence
Gerard I. Evan
GEvan{at}cc.ucsf.edu


   ABSTRACT
Top
ABSTRACT
AN INTRODUCTION TO KSHV
SUMMARY AND PERSPECTIVES
REFERENCES
 
A timely coordination of cellular DNA synthesis and division cycles is governed by the temporal and spatial activation of cyclin-dependent kinases (Cdks). The primary regulation of Cdk activation is through binding to partner cyclin proteins. Several gammaherpesviruses encode a viral homologue of cellular cyclin D, which may function to deregulate host cell cycle progression. One of these is encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) and is called K cyclin or viral cyclin (v-cyclin). v-Cyclin is expressed in most of the malignant cells that are associated with KSHV infection in humans, labelling v-cyclin as a putative viral oncogene. Here are described some of the major structural and functional properties of mammalian cyclin/Cdk complexes, some of which are phenocopied by v-cyclin. In addition, the molecular events leading to orderly progression through the G1/S and G/M cell cycle phases are reviewed. This molecular picture serves as a platform on which to explain v-cyclin-specific functional properties. Interesting but largely speculative issues concern the interplay between v-cyclin-mediated cell cycle deregulation and molecular progression of KSHV-associated neoplasms.

Published online ahead of print on 19 March 2004 as DOI 10.1099/vir.0.79812-0.


   AN INTRODUCTION TO KSHV
Top
ABSTRACT
AN INTRODUCTION TO KSHV
SUMMARY AND PERSPECTIVES
REFERENCES
 
Viruses of the family Herpesviridae cause chronic infections that recur when immune surveillance is compromised, which explains the derivation of their name from the Greek word herpein meaning ‘to creep’. To date, eight human herpesviruses are known, of which Kaposi's sarcoma-associated herpesvirus (KSHV) is the most recently identified (Human herpesvirus 8).

KSHV was first detected in Kaposi's sarcoma (KS) (Chang et al., 1994), a skin tumour of endothelial origin often found in immunosuppressed patients (Boshoff & Weiss, 2001). KSHV is now accepted to be the transmissible agent of KS (Sarid et al., 1999). Since then, KSHV has also been found to be associated with a rare form of B cell lymphoma called primary effusion lymphoma (PEL) or body cavity-based lymphoma (Cesarman et al., 1995) and an unusual B cell plasmablast disease called multicentric Castleman's disease (Soulier et al., 1995).

KSHV shows sequence similarity to oncogenic gammaherpesviruses, including Epstein–Barr virus (Moore et al., 1996). Its genome encodes at least 81 open reading frames (ORFs), of which 66 show significant sequence similarity to ORFs of the rhadinovirus herpesvirus saimiri (HVS), a squirrel monkey virus (Russo et al., 1996c). This classifies KSHV in the family Herpesviridae, subfamily Gammaherpesvirinae, genus Rhadinovirus. Besides HVS and KSHV, this family includes mouse herpesvirus 68 (MHV68), equine herpesvirus 2 and viruses in primates (Lacoste et al., 2000).

All rhadinoviruses contain ORFs with striking homology to cellular genes. These genes are often unspliced, suggesting that they represent captured host cell RNAs. They encode proteins that control DNA synthesis, immune regulation, apoptosis or cell cycle progression (Moore & Chang, 1998). HVS, MHV68 and KSHV all encode a cyclin D homologue with properties that overlap with but extend the function of D-type cyclins. We focus here on the KSHV cyclin, as it serves as a prototype of virus-mediated deregulation of the cell cycle.

Expression of cyclins and cyclin-dependent kinases
Cell cycle transitions and exit from G0 are driven by activities of cyclin/cyclin-dependent kinase (Cdk) complexes. Mammalian G1 cyclins D and E mediate progression through G1/S phases. Three D-type cyclins exist (cyclin D1, D2 and D3), which are expressed differently in various cell lineages, with most cells expressing cyclin D3 and either D1 or D2 (Sherr, 1993). No differential roles for these cyclins have yet been recognized and evidence from mice expressing only a single D-type cyclin suggests that they are functionally redundant in mouse development (Ciemerych et al., 2002). Two types of cyclin E (E1 and E2) exist, which show overlapping expression patterns in mouse tissues and can be co-overexpressed in human tumours (Geng et al., 2001). Future research will elucidate whether any of their functions are distinct.

Mitotic cyclins A and B mediate progression through the S/G2/M phases. Cyclin A1 is expressed in meiosis and early embryogenesis, whereas cyclin A2 is found in proliferating somatic cells (Yang et al., 1997). Cyclin B2 probably plays a role in Golgi remodelling during mitosis (Jackman et al., 1995), while cyclin B1 controls other functions of this cyclin type. Additional cyclins exist (totalling around 16), for many of which binding partners and functions have yet to be identified.

At present, nine mammalian Cdks with known functions have been identified (Morgan, 1997), only four of which (Cdk1, -2, -4 and -6) are directly involved in cell cycle control. Cdk7 contributes indirectly by acting as a Cdk-activating kinase (CAK) that phosphorylates other Cdks (see below). Since Cdk expression levels are relatively constant throughout the cell cycle, the primary regulation of Cdk activity is governed by sequential synthesis, post-translational modification and degradation of cyclins.

D-type cyclins are short-lived proteins whose synthesis and assembly with Cdk4 or Cdk6 in G1 is dependent on mitogenic signalling (Hitomi & Stacey, 1999). Cyclin D/Cdk activity persists through the first and subsequent cycles as long as mitogenic stimulation continues (Matsushime et al., 1991). Cyclin E protein levels peak at the G1/S progression, followed by an increase in cyclin A levels in the S phase. Both cyclin E and A interact with and activate Cdk2, while cyclin A can also bind Cdk1 (Lees & Harlow, 1993). At the G2/M boundary, cyclin B levels increase, resulting in activation of its partner, Cdk1. This fluctuation in cyclin expression and resultant oscillation in Cdk activity (Fig. 1) form the basis of a coordinated cell cycle progression and a platform for more subtle regulatory controls.



View larger version (31K):
[in this window]
[in a new window]
 
Fig. 1. Oscillation of cyclin expression and cyclin/Cdk complex formation through phases of the cell cycle.

 
Structure of cyclin and Cdk catalytic subunits
Cyclins are a remarkably diverse family of proteins, ranging in size from about 35 to 90 kDa. Sequence homology is concentrated in a 100 amino acid stretch, known as the ‘cyclin box’, which is necessary for Cdk binding and activation (Kobayashi et al., 1992; Lees & Harlow, 1993). Thus far, cyclin structures of bovine and human cyclin A, cyclin H and three viral cyclin D homologues have been described (Brown et al., 1995; Card et al., 2000; Jeffrey et al., 1995, 2000; Kim et al., 1996; Schulze-Gahmen et al., 1999). A comparison of these structures suggests that the core of all cyclins contains two compact domains of five helices, called the ‘cyclin fold’ (Fig. 2). The first helix bundle corresponds to the conserved cyclin box. This central fold is flanked by additional helices at the N and C termini, whose position and secondary structure vary in different cyclins.



View larger version (26K):
[in this window]
[in a new window]
 
Fig. 2. Structural basis of the modulation of Cdk activity by cyclin binding and phoshorylation. Structure of human monomeric Cdk2 or cyclin A/Cdk2/ATP complex depicting conserved motifs in cyclin and Cdk proteins. Crystal structure images are adapted from Morgan (1997) and Jeffrey et al. (2000). Cyclin binding to the Cdk subunit changes the catalytic cleft to an active conformation by removing the T-loop such that substrate can bind and by moving the PSTAIRE helix into the cleft so that ATP is bound properly. CAK phosphorylation of Cdk2 Thr-160 residue is counteracted by the Cdk-associated phosphatase, KAP. Wee1/Myt1 protein kinases phosphorylate Thr-14 and Thr-15 residues, which is counteracted by the Cdc25 phosphatase. Modifications in green represent Cdk activation events, modifications in red represent inhibitory events.

 
Cdks are closely related in size (35–40 kDa) and sequence (>40 % identity) and have the same overall fold as other eukaryotic protein kinases. Monomeric Cdk2 consists of an N-terminal lobe rich in {beta}-sheets (N lobe), a C-terminal lobe rich in {alpha}-helices (C lobe) and a deep catalytic cleft at the junction of the lobes (De Bondt et al., 1993). Crystallized cyclin/Cdk6 shows a similar Cdk structure, suggesting that the structural features of Cdk2 are conserved in all Cdks (Jeffrey et al., 2000; Schulze-Gahmen & Kim, 2002). The catalytic activity of the monomeric Cdk subunit is restrained by two mechanisms. First, a large flexible loop (T-loop) on the C-terminal lobe obstructs substrate binding at the catalytic cleft. Secondly, a stretch of helical amino acids in the N-terminal lobe (PSTAIRE helix), which contains residues required for ATP phosphate binding, is directed away from the cleft (De Bondt et al., 1993) (Fig. 2).

v-Cyclin is a cyclin D homologue.
The viral homologue of cellular cyclin D encoded by KSHV is called K cyclin or viral cyclin (v-cyclin). The v-cyclin sequence shows around 53 % sequence similarity to cyclin D2, with the highest level of homology around the cyclin box (Li et al., 1997). This, together with the ability of v-cyclin to bind and activate Cdk4 and Cdk6 and direct their kinase activity towards Rb (Chang et al., 1996; Godden-Kent et al., 1997; Li et al., 1997), shows that v-cyclin resembles D-type cyclins both at the structural and at the functional level.

Regulatory mechanisms governing cyclin/Cdk activity
Cdk activation by cyclin binding
Cdk activity is regulated through multiple mechanisms, the primary mechanism being its binding to the cyclin subunit. The crystal structure of the human Cdk2/cyclin A1 complex revealed that cyclin binding changes the Cdk2 T-loop structure and position such that it no longer obstructs the catalytic cleft. Cyclin binding also rotates the PSTAIRE helix and moves it into the catalytic cleft, resulting in the correct positioning of the ATP-binding catalytic residues (Jeffrey et al., 1995) (Fig. 2). Although the major cyclin/Cdk binding and structural characteristics are conserved, variations in the length of the Cdk PSTAIRE helix and position of the N-terminal cyclin helix exist (Jeffrey et al., 2000; Kim et al., 1996). This may underlie the specificity of Cdk4/6 for D-type cyclins, Cdk2 for cyclins A and E and Cdk1 for cyclin B.

v-Cyclin preferentially interacts with Cdk6.
In vitro binding and kinase assays indicate that v-cyclin mainly forms active complexes with Cdk6 (Godden-Kent et al., 1997; Li et al., 1997). The preference for Cdk6 is remarkable in light of the KSHV host cell repertoire, since lymphoid cells express relatively high levels of Cdk6 and cyclin D/Cdk6 activity predominates in such cells (Meyerson & Harlow, 1994). Cdk6 expression is also detectable in KS lesions (Ojala et al., 1999).

v-Cyclin/Cdk6 complexes show enhanced kinase activity.
v-Cyclin/Cdk6 complexes show enhanced kinase activity towards their substrates as measured by in vitro kinase assays when compared with cyclin D/Cdk complexes (Jeffrey et al., 2000; Li et al., 1997; Swanton et al., 1999). This could be the result of increased interactions between v-cyclin and Cdk, with the more stable active conformation accounting for an increased kinase activity (Jeffrey et al., 2000).

v-Cyclin/Cdk6 complexes phosphorylate Cdk2-type substrates.
v-Cyclin/Cdk6 complexes phosphorylate an extended array of substrates that are not normally targets of cyclin D/Cdk6. These include the cyclin E/Cdk2 targets p27, histone H1 and Cdc25A (Ellis et al., 1999; Mann et al., 1999) and the cyclin A/Cdk2 targets of the replication machinery, Cdc6 and Orc1 (Laman et al., 2001). The activity of v-cyclin/Cdk6 therefore mimics the combined activities of G1 and S phase cyclin/Cdk complexes. What explains this expanded substrate specificity? The substrate specificity of Cdk2 differs depending on its binding to cyclin E or A, implying that the cyclin subunit is likely to contribute (Sarcevic et al., 1997; Zarkowska et al., 1997). Indeed, substrates bind to a conserved binding groove on the cyclin, called the hydrophobic patch (Schulman et al., 1998). Another potential determinant is the conformation of the catalytic site (Brown et al., 1999). By inference, v-cyclin binding to substrates as well as the effect of v-cyclin on conformation of the Cdk6 catalytic cleft are likely to determine its substrate repertoire.

Regulation of Cdk activity by phosphorylation
Complete activation of Cdk activity is mediated by phosphorylation of a conserved threonine residue (Thr-160 in Cdk2, Thr-161 in Cdk1) in the T-loop by the CAK enzyme (Fig. 2). The major mammalian candidate for CAK is the cyclin H/Cdk7/Mat1 complex (Nigg, 1996). CAK phosphorylation moves the T-loop outwards, resulting in additional Cdk–cyclin contacts and probably increases potential for substrate binding (Russo et al., 1996b). Dephosphorylation of this residue can be achieved by the Cdk-associated phosphatase, KAP (Poon & Hunter, 1995).

In addition, Cdks undergo inhibitory phosphorylation on the Thr-14 and Tyr-15 residues located in the roof of the ATP phosphate-binding site (Fig. 2). It is likely that this reduces the affinity for ATP, thereby preventing Cdk catalytic activity (Endicott et al., 1999). Phosphorylation of these sites is mediated by the Wee1 and Myt1 protein kinases (Lew & Kornbluth, 1996) and dephosphorylation is carried out by phosphatases of the Cdc25 family. Cdc25A and B are active during G1/S and Cdc25C is the mitotic isoform. Not surprisingly, this extensive phosphorylation network is amenable to various regulatory mechanisms, which are central to the execution of cell cycle checkpoints.

Non-CAK-phosphorylated v-cyclin/Cdk6 complexes are active in vitro.
Unlike D-type cyclin/Cdk complexes, v-cyclin/Cdk6 complexes do not require CAK phosphorylation to generate active holoenzymes in vitro (Child & Mann, 2001; Kaldis et al., 2001), which renders v-cyclin function less dependent on host kinase activity compared with cyclin D. Activation is, however, incomplete, because non-CAK-phosphorylated v-cyclin/Cdk6 does not target the full range of retinoblastoma protein (Rb) phosphorylation sites and does not enable S-phase entry (Child & Mann, 2001).

Inhibition by Ink4-family proteins
The Ink4 family of Cdk inhibitors (CKIs) contains four members, named according to their molecular masses, p16Ink4a, p15Ink4b, p18Ink4c and p19Ink4d (p16, p15, p18 and p19) and their ability to inhibit Cdk4. These CKIs specifically inhibit Cdk4 and Cdk6 and do not bind Cdk2 or Cdk1. Ink4 proteins are composed of multiple ankyrin repeats and bind to the non-catalytic side of Cdk4 and Cdk6 opposite the cyclin D binding site (Russo et al., 1998). Binding of Ink4 inhibitors to Cdk4 or Cdk6 prevents Cdk interaction with cognate D-type cyclins: Ink4 binding induces allosteric changes by rotating the two Cdk4/6 lobes 15° in the vertical axis, thus mislocating the cyclin-interacting sequences and distorting the ATP binding site (Jeffrey et al., 2000) (Fig. 3).



View larger version (30K):
[in this window]
[in a new window]
 
Fig. 3. Graphic representation of cyclin/Cdk inhibition by Ink4 and the Cip/Kip family of inhibitors, based on crystal structures of the binary cyclin A/Cdk2 complex (Jeffrey et al., 1995), ternary p27/cyclin A/Cdk2 (Russo et al., 1996a) and p18/viral cyclin/Cdk6 (Jeffrey et al., 2000) complexes. The crystal structure of v-cyclin serves as a model for D-type cyclin structure, as cellular D-type cyclin could not be crystallized (Jeffrey et al., 2000). A model of cyclin/Cdk inhibition by CKIs is deduced by comparing the structures of the three complexes (Jeffrey et al., 2000). The Ink4 inhibitors bind to Cdk4 or Cdk6 and prevent their interaction with D-type cyclins by rotation of the Cdk lobes 15° in the vertical axis. Cip/Kip inhibitors bind both cyclin and Cdk subunits, which disrupts Cdk catalytic activity by disruption of the conformation of the Cdk subunit, the ATP binding site and the catalytic cleft. The T-loop is indicated in red and the PSTAIRE helix in green.

 
v-Cyclin/Cdk6 complexes are less susceptible to inhibition by Ink4 proteins.
Ink4 proteins are unable to inhibit v-cyclin/Cdk6-driven kinase activity towards Rb in protein extracts from baculovirus-infected Spodoptera frugiperda (Sf9) cells (Swanton et al., 1997). Insight into the lack of inhibition by Ink4 proteins was provided by the crystallization of the v-cyclin/Cdk6/p18 ternary complex (Jeffrey et al., 2000). The authors showed that CAK-phosphorylated Cdk6/v-cyclin complexes are resistant to inhibition by p18 and suggested that CAK phosphorylation of Cdk6 increases the interactions between the N and C lobes of Cdk6. This, together with increased interactions between v-cyclin and the Cdk6 C lobe could stabilize the active arrangement of the catalytic cleft and prevent its disruption upon Ink protein binding. In agreement with this, the interface of the HVS viral cyclin/Cdk6 complex is 20 % larger than in the cyclin A/Cdk2 complex (Schulze-Gahmen et al., 1999).

Inhibition by Cip/Kip family proteins
Cdk inhibitors of the Cip/Kip family are more broadly acting Cdk inhibitors. This family consists of three members, p21Cip1, p27Kip1 and p57Kip1 (p21, p27 and p57). p21 and p27 are potent inhibitors of cyclin D-, E- and A- and weak inhibitors of cyclin B-associated kinase activity (el-Deiry et al., 1993; Gu et al., 1993; Noda et al., 1994; Xiong et al., 1993). p57 is thought to be functionally analogous to other Cip/Kip proteins, but fewer studies have focused on p57.

The Cip/Kip family inhibitors can bind isolated cyclin and Cdk subunits independently, although their binding affinity for cyclin/Cdk complexes is higher (Chen et al., 1996; Harper et al., 1995; Lin et al., 1996; Toyoshima & Hunter, 1994). The Cip/Kip N-terminal moiety is necessary and sufficient to bind to and inhibit Cdk complexes. This N-terminal region contains two subsections: a short motif required for cyclin binding (Cy1) and a more complex segment that binds the Cdk subunit (Chen et al., 1996; Fotedar et al., 1996). The crystal structure of an N-terminal p27 peptide in complex with cyclin A/Cdk2 provided a breakthrough in our understanding of the inhibitory mechanism (Russo et al., 1996a). The p27 peptide stretches across the top of the cyclin/Cdk complex in an extended conformation (Fig. 3). The N-terminal part of the p27 peptide binds a conserved hydrophobic groove on the cyclin box. This p27/cyclin interaction is likely to serve as an anchor to facilitate subsequent p27/Cdk binding, since it does not require conformational changes. The C-terminal part of the peptide interacts with the upper Cdk lobe, disrupting the conformation of the ATP binding site. In addition, a p27 helix inserts into the catalytic cleft and prevents ATP binding. Together, these interactions disrupt any catalytic potential of the cyclin/Cdk complex.

Multiple experiments have indicated that p21 and p27 can associate with active cyclin D/Cdk complexes and may therefore act as assembly factors (Sherr & Roberts, 1999). However, p21/p27–/ cells proliferate and are susceptible to p16-mediated growth inhibition (Cheng et al., 1999), implying that p21 and p27 are not strictly required for cyclin D/Cdk activity. Furthermore, the stability of cyclin D and Cdks is significantly reduced in the absence of p21 and p27 (Bagui et al., 2000; Cheng et al., 1999), complicating assessment of the effect of Cip/Kip binding on cyclin D/Cdk complex activity. Purification and crystallization of the cyclin D/Cdk/CKI complex will clarify the properties of the holoenzyme.

v-Cyclin/Cdk6 complexes are less susceptible to inhibition by Cip/Kip proteins.
Similar to Ink4 inhibitors, Cip/Kip proteins are also unable to inhibit v-cyclin/Cdk6-driven kinase activity towards Rb in protein extracts from baculovirus-infected Sf9 cells (Swanton et al., 1997). The resistance to Cip/Kip proteins correlates with the lack of p21/p27 binding to v-cyclin/Cdk complexes. This conclusion is supported by the superimposition of the cyclin A/p27 structure over the HVS viral cyclin structure (Schulze-Gahmen et al., 1999). While the p27 binding pocket of cellular cyclins is highly conserved, viral cyclins contain substitutions in residues that are crucial for p27 binding. Notably, Glu-66 of cyclin D (Glu-220 of cyclin A), which forms a hydrogen bond and a salt bridge with p27, is substituted for Ser-60 in v-cyclin (Swanton et al., 1999). This results in loss of the electronegative character of the p27 binding groove and reduces the number of possible contacts between v-cyclin and p27, together decreasing the likelihood of p27 binding to v-cyclin (Schulze-Gahmen et al., 1999; Swanton et al., 1999).

Cyclin/Cdk localization
Since many critical cyclin/Cdk targets are nuclear proteins, nucleocytoplasmic shuttling is a means of regulating cyclin/Cdk activity (Yang & Kornbluth, 1999). The G1/S cyclins A and E are expressed predominantly in the nucleus (Ohtsubo et al., 1995; Pines & Hunter, 1991), consistent with their roles in DNA replication and S-phase progression. In contrast, cyclin B is exclusively cytoplasmic during G1/S, followed by a dramatic nuclear relocation upon mitotic entry (Takizawa & Morgan, 2000). Differences in the shuttling behaviour of these cyclins are a consequence of distinct nuclear import and export mechanisms and speeds (Jackman et al., 2002).

Cyclin D/Cdk complexes accumulate in the nucleus throughout the G1 phase but then relocate to the cytoplasm during the remainder of interphase (Baldin et al., 1993). Since neither cyclins nor Cdks contain canonical nuclear localization sequences (NLSs), nuclear import may be mediated via their binding to NLS-containing proteins. Suggested cyclin D nuclear import factors are Cip/Kip proteins, which contain an NLS and promote cyclin D/Cdk nuclear accumulation (Cheng et al., 1999; LaBaer et al., 1997). However, absence of both p21 and p27 does not abolish cyclin D1 nuclear import (Cheng et al., 1999) and, instead, p21 and p27 have been suggested to promote cyclin D1 nuclear accumulation via inhibition of a glycogen synthase kinase (GSK)-3{beta}-triggered nuclear export mechanism (Alt et al., 2002). Another candidate import factor is the p34SEI-1 protein that binds to cyclin D1/Cdk4 complexes and contains an NLS (Sugimoto et al., 1999). Yet another possibility is that cyclin D contains an unidentified NLS, as suggested for cyclin E (Moore et al., 1999).

How is nuclear accumulation of v-cyclin regulated?
Cyclin D1 nuclear export is triggered upon GSK-3{beta}-mediated phosphorylation of Thr-286 in cyclin D1 (Alt et al., 2002). v-Cyclin does not contain a residue homologous to the cyclin D1 Thr-286 residue, perhaps implying that v-cyclin evades nuclear export. This could explain why nuclear accumulation of v-cyclin is pronounced (Child & Mann, 2001), even though it does not bind p21/p27 CKIs (Swanton et al., 1997).

Cyclin/Cdk/CKI stability
While Cdks are expressed constitutively and are relatively stable, cyclins are subject to regulated degradation. The degradation of cyclins is regulated by the ubiquitin–proteasome system. Ubiquitination involves the covalent attachment of ubiquitin chains to lysine residues in the target protein, which promotes its recognition and degradation by the proteasome (Harper et al., 2002) (Fig. 4A). Two ubiquitin ligases regulate cell cycle progression: the Skp/Cullin/F-box (SCF) complex targets proteins at the G1/S/G2 phases and the anaphase-promoting complex (APC) acts at G2/M (Fig. 4B). Target specificity of these ligases is governed by their binding to adaptor proteins. These comprise F-box sequence motif-containing proteins such as Skp2 in the case of SCF (SCFskp2), or WD-40 repeat-containing proteins such as Cdh1 or Cdc20 in case of APC (APCCdh1, APCCdc20).



View larger version (29K):
[in this window]
[in a new window]
 
Fig. 4. Ubiquitination of cell cycle regulators. (A) Simplified scheme of the ubiquitination reaction. E1 uses ATP to form a high-energy thiol ester with ubiquitin (Ub), which is transferred to a cysteine residue on the E2 ubiquitin-conjugating enzyme. E2 assembles with an E3 ubiquitin ligase to transfer ubiquitins to one or more lysines on the substrate. Multiple rounds of ubiquitination lead to the formation of poly-ubiquitin chains that are recognized by the proteasome. (B) Temporal control and cell cycle targets of the APC and SCF ubiquitin ligase complexes. Adaptor proteins that determine SCF or APC substrate specificity are shown in superscript; the adaptor protein specifying cyclin D degradation has not yet been identified. Adapted from Harper et al. (2002).

 
Many SCF substrates are phosphorylated prior to ligase recognition. The degradation of cyclin D1 is initiated upon phosphorylation of Thr-286 by GSK-3{beta} (Diehl et al., 1997, 1998). Cyclin E/Cdk2 complexes can initiate cyclin E degradation via phosphorylation of Thr-380, thus forming a negative feedback loop to limit cyclin E expression to late G1 (Clurman et al., 1996; Won & Reed, 1996). Degradation of p27 is initiated by cyclin E/Cdk2-catalysed phosphorylation of Thr-187 (Vlach et al., 1997). The APC mediates degradation of cyclin A after nuclear envelope breakdown in prometaphase, while cyclin B1 degradation occurs during the metaphase to anaphase transition (Clute & Pines, 1999; den Elzen & Pines, 2001; Geley et al., 2001) Interestingly, the APC is activated upon phosphorylation of APC core subunits by Cdk2 and Cdk1 itself (Morgan, 1999). Thus, protein degradation is initiated by cell cycle proteins, ensuring timed regulation of protein activity.

Is v-cyclin more stable than cyclin D?
v-Cyclin does not contain residues homologous to the C-terminal cyclin D1 Thr-286 residue or cyclin E Thr-380 residue that have been implicated in the destruction of these cyclins. However, a direct comparison of the stability of v-cyclin compared with cyclin D1 has not yet been performed.

G1/S progression
The retinoblastoma protein
The most recognized function of cyclin D/Cdk activity is inactivation of the Rb tumour suppressor. Rb and its relatives p107 and p130 are called ‘pocket’ proteins (Harbour & Dean, 2000), reflecting the folding of conserved domains around a pocket that constitutes the protein-binding site. The most established function of pocket proteins is interaction with and inhibition of the E2F family of transcription factors.

Rb is thought to repress E2F-dependent transcription by at least two mechanisms. First, Rb directly binds the transactivation domain of E2F, thus blocking recruitment of the transcription machinery (Helin et al., 1993). Secondly, Rb binding to E2F actively represses transcription via its interaction with factors that influence chromatin structure. These include histone deacetylases (HDACs) (Kouzarides, 1999) and components of the SWI/SNF chromatin-remodelling complex (Dunaief et al., 1994; Singh et al., 1995; Zhang et al., 2000). Together, these factors mediate tight assembly of chromatin in nucleosomes, inhibiting access of the transcriptional apparatus.

Rb contains 16 potential Cdk phosphorylation sites, which regulate the binding of distinct proteins (Knudsen & Wang, 1997). Complete phosphorylation of Rb relieves its binding to E2F, triggering E2F-dependent transcription of G1/S genes. Successive phosphorylation by cyclin D/Cdk complexes in early G1 and cyclin E/Cdk2 complexes in late G1 is necessary for hyperphosphorylation of Rb (Lundberg & Weinberg, 1998), and phosphorylation by cyclin A/Cdk2 may maintain Rb hyperphosphorylation during S phase (Sherr, 1996). Although based on overexpression studies, a potential model is that phosphorylation by cyclin D/Cdk4 first disrupts the association of Rb with HDAC, thereby allowing cyclin E expression. The interaction between Rb and SWI/SNF is, however, maintained and is sufficient to repress the cyclin A promoter. Upon phosphorylation by cyclin E/Cdk2, Rb repression of the cyclin A promoter is relieved (Harbour et al., 1999; Zhang et al., 2000), ensuring orderly activation of cyclin E and A in S phase.

The E2F family of transcription factors
The E2F family of transcription factors regulates the transcription of genes involved in cell cycle progression, nucleotide biosynthesis and DNA replication. Six E2F family proteins exist (E2F1–6) which heterodimerize with DP proteins (DP1 and DP2) in all possible combinations (Trimarchi & Lees, 2002). E2F4 and E2F5 in complex with p130 mediate the transcriptional repression of E2F-responsive genes in quiescent or differentiated cells (Trimarchi & Lees, 2002). In contrast, E2F1, E2F2 and E2F3 are expressed specifically in dividing cells where they interact with Rb and p107. They are potent transcriptional activators and cells lacking expression of E2F1, E2F2 and E2F3 are unable to proliferate (Wu et al., 2001), confirming their role in S-phase progression.

The complexity of E2F-triggered responses is illustrated by results from microarray analyses (Ishida et al., 2001; Muller et al., 2001), which identified E2F-induced genes that function during mitosis (e.g. Cdc2 and cyclin B), as well as genes involved in apoptosis and development. In addition, analysis of E2F-repressed genes in quiescent cells identified mitotic genes, including regulators of cytokinesis (e.g. polo-kinase), chromosome condensation and segregation (e.g. securin) (Ren et al., 2002). These results suggest a broader role for E2Fs in mitosis as well as G1/S.

Orderly progression through G1/S phases
A (simplified) scheme of G1/S progression can be drawn based on the assimilation of the previous information (Fig. 5). Cell cycle gene expression is suppressed in quiescent cells via the activity of p130/E2F4/E2F5 complexes. Upon mitogen stimulation, cyclin D levels rise and cyclin D/Cdk activity increases. In addition, Cip/Kip protein increases promote cyclin D nuclear accumulation and stability. Here, cyclin D/Cdk complexes initiate hypophosphorylation of Rb, which stimulates cyclin E expression. Cyclin E/Cdk2 activity also increases because the Cip/Kip inhibitors are sequestered away from cyclin E/Cdk towards cyclin D/Cdk complexes. This drives a feedback loop towards further phosphorylation of Rb, further amplified by degradation of p27 upon cyclin E/Cdk2 phosphorylation. Together, these signals culminate in transcriptional activation of genes including cyclin A and E2F itself.



View larger version (36K):
[in this window]
[in a new window]
 
Fig. 5. Schematic representation of major events regulating G1/S progression. Exit from G0 is associated with a switch in pocket protein/E2F complexes and loss of their binding to chromatin remodelling factors. Activation of cyclin D/Cdk complexes upon mitogenic signalling is counteracted by the activity of Ink4 Cdk inhibitors, while Cip/Kip inhibitors may serve as assembly factors. Cyclin D/Cdk complexes initiate phosphorylation of Rb, which is likely to trigger transcriptional activation of cyclin E. Rb phosphorylation is completed by cyclin E/Cdk2 phosphorylation, releaving repression of genes required for G1/S progression, amongst which is cyclin D. Cyclin A- and E-associated kinase activity can also directly trigger DNA replication, although critical targets remain unclear. Dashed lines represent feedback loops that consist of the activation of ubiquitin-dependent degradation. Many additional fine-tuning regulations exist and this diagram is therefore highly simplified.

 
Interestingly, cyclin E, but not cyclin D, is required for G1/S progression in cells lacking Rb function (Ohtsubo et al., 1995) and cyclin E overexpression is sufficient to overcome growth arrest induced by a phosphorylation-resistant Rb mutant (Lukas et al., 1997). This implies that the main downstream target of cyclin D/Cdk activity is Rb, while cyclin E/Cdk2 has additional S-phase targets. Indeed, cyclin E, like cyclin A, triggers phosphorylation of DNA replication proteins such as Cdc6, directly activating DNA replication (Bell & Dutta, 2002). This simple model is, however, challenged by findings that mice lacking cyclin E1 and E2 or Cdk2 expression are viable and that cell cycle progression is uncompromised in cells derived from these mice (Berthet et al., 2003; Geng et al., 2003; Ortega et al., 2003). Specific cyclin/Cdk activities may therefore exhibit previously unappreciated functional redundancies.

Active cyclin D/E- and A-dependent kinases are regulated by negative feedback loops: cyclin E/Cdk2 complexes phosphorylate cyclin E, directing it to SCF-mediated ubiquitination. Cyclin A/Cdk2 phosphorylation of components of the APC may initiate proteolysis of cyclin A itself. Importantly, E2Fs are inactivated around S/G2 by at least two mechanisms. First, cyclin A/Cdk2 phosphorylation of E2F1 inhibits its DNA binding activity (Krek et al., 1994). Secondly, E2F1 undergoes SCFSkp2-dependent ubiquitination and degradation (Marti et al., 1999). Negative regulation of G1/S progression can also be enforced upon CKI induction, for example upon the execution of checkpoints.

v-Cyclin expression deregulates G0/G1/S control
v-Cyclin/Cdk complexes exhibit properties that extend those of cellular cyclins and potentially enable productive KSHV propagation. It is unknown whether KSHV infects proliferating progenitor or resting quiescent cells that contain high levels of CKIs. If the latter is true, then v-cyclin could still form active complexes with endogenous Cdks and stimulate exit from G0. In addition, its broadened substrate specificity to include G1- and S-phase targets would allow progression through G1 and initiation of S phase. Functional studies support this hypothesis, as v-cyclin expression induces S-phase entry in quiescent cells and in p16- or p27-overexpressing, G1-arrested cells (Swanton et al., 1997). Furthermore, the evasion of Cdk inhibition by v-cyclin/Cdk complexes would be beneficial in case of the activation of anti-viral tumour suppressor pathways by the host cell. Importantly, transgenic expression of v-cyclin promotes tumorigenesis (Verschuren et al., 2002), showing that v-cyclin has intrinsic oncogenic properties that can enhance host cell proliferation.

v-Cyclin/Cdk6 phosphorylation of replication proteins may also directly control DNA replication. Indeed, addition of v-cyclin, but not cyclin D, to isolated G1 nuclei triggered replication initiation in a manner analogous to cyclin A (Laman et al., 2001). Initiation starts with the assembly of pre-replicative complexes at replication origins in a reaction known as ‘licensing’ (Bell & Dutta, 2002). Further elucidation of DNA replication mechanisms in human cells will clarify how v-cyclin controls origin licensing and/or firing.

Cell cycle progression upon v-cyclin expression still relies on the host cell cycle machinery. Cells expressing a p27 T187A mutant that cannot be degraded cannot complete S phase even when v-cyclin is expressed (Ellis et al., 1999; Mann et al., 1999). This implies that activation of endogenous Cdks upon p27 degradation is required for full S-phase progression. Complementing these data, v-cyclin expression is unable to bypass a block on endogenous Cdk2 imposed by the chemical Cdk inhibitor roscovitine or by dominant-negative Cdk2 (Ellis et al., 1999). Another factor is the dependence of v-cyclin/Cdk activity on CAK phosphorylation by endogenous enzyme (Jeffrey et al., 2000; Kaldis et al., 2001). Thus, v-cyclin expression is likely to create an environment that is more conducive to (viral) DNA replication, but requires endogenous cyclin/Cdk activity for full cell cycle progression.

G2/M progression
Mitotic entry
Mitotic events such as nuclear envelope breakdown coincide with cyclin B/Cdk1 nuclear import (Hagting et al., 1999). Cyclin B nuclear localization is thought to be initiated upon its phosphorylation by cyclin B/Cdc2 itself or polo-kinase (Plk). Plk phosphorylation of Cdc25C also stimulates the dephosphorylation of inhibitory phosphates on Cdk2, further enhancing cyclin B/Cdk1 activity (Kumagai & Dunphy, 1996; Qian et al., 2001) (Fig. 6). Targets of cyclin B/Cdc2 include structural proteins and nucleolar proteins that regulate nuclear envelope breakdown and spindle assembly (Nigg, 1993).



View larger version (32K):
[in this window]
[in a new window]
 
Fig. 6. Schematic representation of major events regulating G2/M progression. Mitotic entry is initiated upon nuclear import of cyclin B/Cdk1 complexes, which may be triggered by Plk- or cyclin B/Cdk1-mediated phosphorylation of cyclin B protein. Cdc25 phosphatase activation promotes Cdk1 activity by dephosphorylating Cdk2 inhibitory phosphates. Mitotic exit is triggered by the sequential activation of the APCCdc20 and APCCdh1 ubiquitin ligases and the consequent degradation of their substrates. APC activity is regulated by phosphorylation events mediated by, amongst others, Plk, cyclin B/Cdk1 and cyclin A/Cdk2, and Cdc14-mediated dephosphorylation. This model is based on data obtained from various overexpression studies in different model systems. Dashed arrows denote potential (de)phosphorylation events, for which in vivo evidence in human cell systems remains scarce. Meta, metaphase; ana, anaphase; cyto, cytokinesis.

 
Mitotic exit
Mitotic exit is triggered by the APCCdc20-dependent destruction of securin protein, which is required for sister chromatid separation (Nasmyth, 2002). In addition, degradation of cyclins A and B is essential for mitotic progression beyond anaphase (Morgan, 1999), as illustrated by findings that non-degradable versions of cyclin A and B arrest cells in metaphase or anaphase (Geley et al., 2001; Parry & O'Farrell, 2001; Sigrist et al., 1995). Mitotic cyclin degradation is coordinated by the sequential activation of the APCCdc20 and APCCdh1 and, again, oscillations in kinase activity are key (Harper et al., 2002). First, the APCCdc20 complex is activated upon phosphorylation by Plk and cyclin B/Cdk1. This may increase the binding of the Cdc20 adaptor to APC and stimulate APCCdc20 activity towards degradation of cyclins A and B. Plk thus acts as a master regulator of mitosis through triggering both the activation and degradation of cyclin B. Secondly, cyclin A/Cdk2 phosphorylation of Cdh1 inhibits Cdh1 binding to APC and the degradation of cyclin A therefore licenses activation of APCCdh1 and complete degradation of mitotic cyclins (Lukas et al., 1999) (Fig. 6). Thirdly, cytokinesis is executed upon removal of inhibitory phosphates on Cdh1 and cyclin B/Cdk1 mitotic substrates by the Cdc14 phosphatase (Visintin et al., 1998).

Although securin and mitotic cyclins are the best understood APC substrates, a large number of other proteins are degraded by the APC. Examples are Plks themselves and Aurora protein kinases (Bischoff & Plowman, 1999). Both kinases localize to mitotic structures such as centrosomes, which constitute the microtubule organizing centres of the cell (Doxsey, 2001; Hinchcliffe & Sluder, 2001) and mitotic spindles. Deregulation of Aurora and Plk kinases disrupts mitotic exit (Meraldi et al., 2002), and the ability of APCCdh1 to keep their levels in check is therefore important for a proper execution of cytokinesis.

v-Cyclin expression deregulates mitotic progression
v-Cyclin-expressing cells undergo continued DNA synthesis and nuclear division, yet do not undergo cytokinesis (Verschuren et al., 2002). Thus v-cyclin/Cdk complexes, as well as deregulating G1/S progression, also deregulate mitosis. The cytokinesis defect may involve v-cyclin-associated misexpression of mitotic regulators, most likely through an increase of E2F transcriptional targets. Indeed, defects in cell division and concomitant multinucleation have been reported upon overexpression of Plk and Aurora kinases (Meraldi et al., 2002; Mundt et al., 1997; Wang et al., 2002). However, the mechanistic explanation of these results remains unknown.

An outcome of mitotic deregulation in v-cyclin-expressing cells is activation of the p53 tumour suppressor, triggering apoptosis and growth arrest (Verschuren et al., 2002). Activation of p53 occurs in an E2F1- and p19ARF-independent manner and may instead occur as a response to the formation of tetraploid cells. Active p53 would normally trigger a G1 arrest via induction of p21 protein and consequent G1/S Cdk inhibition (Stewart & Pietenpol, 2001). However, v-cyclin/Cdk complexes are refractory to Cdk inhibitors, which most likely explains why v-cyclin-expressing cells become polyploid. The increase in ploidy correlates with an increase in the number of centrosomes, explained by the co-regulation of the centrosome duplication and DNA replication cycles (Hinchcliffe & Sluder, 2001). A second outcome of mitotic deregulation is therefore the induction of genomic instability through centrosome amplifications and consequent spindle defects.


   SUMMARY AND PERSPECTIVES
Top
ABSTRACT
AN INTRODUCTION TO KSHV
SUMMARY AND PERSPECTIVES
REFERENCES
 
v-Cyclin/Cdk complexes exhibit properties that could stimulate the expansion of KSHV-infected cells (Fig. 7). These include functions that deregulate G1/S progression, such as enhanced kinase activity towards Rb, a promiscuous substrate specificity, escape from inhibition by CKIs and initiation of DNA replication. In addition, v-cyclin/Cdk activity may promote genomic instability by disrupting mitotic progression. Counteracting these pro-tumorigenic stimuli, v-cyclin expression sensitizes cells to undergo apoptosis (Ojala et al., 1999; Verschuren et al., 2002), in part by inactivating the anti-apoptotic cellular Bcl-2 pool (Ojala et al., 2000), and triggers a p53-dependent growth arrest (Verschuren et al., 2002). v-Cyclin-expressing cultured cells only survive and expand as an aneuploid population when p53 is inactive. These findings are confirmed in vivo, as Eµ v-cyclin expression drives lymphomagenesis only when the p53 pathway is disrupted (Verschuren et al., 2002), probably via allowing the expansion of a genetically altered population of lymphocytes (Verschuren et al., 2004).



View larger version (29K):
[in this window]
[in a new window]
 
Fig. 7. Deregulation of G1/S and G2/M progression by v-cyclin/Cdk complexes. Activation of cellular Cdks (most likely Cdk6) upon interaction with v-cyclin (v-cyc) triggers various biological responses amongst which are G1/S-specific processes such as phosphorylation and inactivation of the Rb tumour suppressor protein, activation of DNA replication and inactivation of the p27 Cdk inhibitor. v-Cyclin expression also deregulates mitotic progression, perhaps via misexpression and/or deregulation of mitotic kinases, leading to abortive cytokinesis and activation of the p53 tumour suppressor protein. Active p53 triggers (sensitization to) apoptosis and growth arrest. v-Cyclin also sensitizes cells to apoptosis via v-cyclin/Cdk6 phosphorylation and inactivation of cellular Bcl-2 protein. Because v-cyclin/Cdk complexes are insensitive to the action of Cdk inhibitors such as p21, growth-arrested cells lack functional G1 and G2 checkpoints and can therefore undergo continued DNA replication and nuclear division. This most likely explains why v-cyclin-expressing cells become polyploid and exhibit centrosome amplification. Such genomically unstable cells only survive and expand in the absence of p53 to become tumorigenic.

 
A remaining quest is to translate these findings into a physiological role for v-cyclin in KSHV-associated pathogenesis. This is complicated by the lack of a KSHV-permissive system or animal models for pathogenesis. Mutant viruses lacking the expression of the MHV68 viral cyclin show normal latent infection patterns, but inefficient reactivation from latency (Hoge et al., 2000; van Dyk et al., 2000). However, thus far MHV68 cyclin is the only viral cyclin studied in an in vivo context and no deductions for persistent KSHV infection in a physiological context can be made.

Interesting but largely speculative topics of discussion concern the interplay between virally expressed genes. The majority of tumour cells in KSHV-associated diseases are latently infected, with only 1–3 % of the cells showing lytic replication (Zhong et al., 1996). Latent gene expression is highly restricted and encompasses an ‘oncogenic cluster’ of three genes with overlapping transcripts: latency-associated nuclear antigen (LANA), v-cyclin and viral FLICE-inhibitory protein (v-FLIP) (Jenner et al., 2001; Paulose-Murphy et al., 2001). In addition, several RNA transcripts encoding interferon regulatory factors (IRFs) are detected. Since latent gene expression is widespread in KSHV diseases, the combination of latent protein expression may be critical for oncogenesis.

An in vivo functional interaction may exist between the latent proteins LANA and ORF K10 IRF, which bind and inhibit p53 (Friborg et al., 1999; Rivas et al., 2001), and v-cyclin. Indeed, LANA colocalizes with p53 in KS samples (Katano et al., 2001). This, together with the absence of recurrent p53 mutations in KSHV-associated disorders (Carbone et al., 1998; Katano et al., 2001; Kennedy et al., 1998), raises the intriguing possibility that v-cyclin-induced apoptosis and/or growth arrest are inhibited by these proteins. Secondly, LANA binds the Rb protein and activates E2F-dependent transcription (Radkov et al., 2000), and LANA negatively regulates GSK-3{beta} function to increase {beta}-catenin protein stability and transcriptional activity (Fujimuro et al., 2003), constituting further proliferative stimuli that could enhance v-cyclin function. Related to this, inhibition of GSK-3{beta} by LANA could promote the nuclear localization of cellular cyclin D. Thirdly, latent expression of v-FLIP may cooperate with v-cyclin to promote KSHV tumorigenesis via its ability to inhibit death receptor-triggered lymphocyte apoptosis (Djerbi et al., 1999).

The establishment of KSHV gene functions in vivo is further complicated by the fact that infected cells may support the growth of uninfected cells in trans (Ensoli & Sturzl, 1998). Endothelial cells expressing the KSHV-encoded G protein-coupled receptor (GPCR), for example, cooperate with cells expressing v-cyclin in sarcomagenesis through paracrine mechanisms (Montaner et al., 2001). This emphasizes the need to assess KSHV gene function in a physiological context.

While 10 % of spindle cells in early KS lesions are KSHV-positive (Dupin et al., 1999), around 90 % of the spindle cells in late stage nodular lesions are KSHV-infected, suggesting that the virus provides a growth advantage to infected cells (Boshoff & Weiss, 2001). Furthermore, KS and PEL begin as polyclonal hyperplasias that develop into monoclonal tumours (Gill et al., 1998; Judde et al., 2000). The all-encompassing question is therefore whether v-cyclin expression promotes the tumorigenic evolution of KSHV-infected cells by triggering genomic instability and clonal outgrowth of cells with an enhanced proliferative capacity.


   REFERENCES
Top
ABSTRACT
AN INTRODUCTION TO KSHV
SUMMARY AND PERSPECTIVES
REFERENCES
 
Alt, J. R., Gladden, A. B. & Diehl, J. A. (2002). p21Cip1 promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export. J Biol Chem 277, 8517–8523.[Abstract/Free Full Text]

Bagui, T. K., Jackson, R. J., Agrawal, D. & Pledger, W. J. (2000). Analysis of cyclin D3–cdk4 complexes in fibroblasts expressing and lacking p27kip1 and p21cip1. Mol Cell Biol 20, 8748–8757.[Abstract/Free Full Text]

Baldin, V., Lukas, J., Marcote, M. J., Pagano, M. & Draetta, G. (1993). Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 7, 812–821.[Abstract]

Bell, S. P. & Dutta, A. (2002). DNA replication in eukaryotic cells. Annu Rev Biochem 71, 333–374.[CrossRef][Medline]

Berthet, C., Aleem, E., Coppola, V., Tessarollo, L. & Kaldis, P. (2003). Cdk2 knockout mice are viable. Curr Biol 13, 1775–1785.[CrossRef][Medline]

Bischoff, J. R. & Plowman, G. D. (1999). The Aurora/Ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol 9, 454–459.[CrossRef][Medline]

Boshoff, C. & Weiss, R. A. (2001). Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus. Philos Trans R Soc Lond Ser B Biol Sci 356, 517–534.[Medline]

Brown, N. R., Noble, M. E., Endicott, J. A., Garman, E. F., Wakatsuki, S., Mitchell, E., Rasmussen, B., Hunt, T. & Johnson, L. N. (1995). The crystal structure of cyclin A. Structure 3, 1235–1247.[Medline]

Brown, N. R., Noble, M. E., Endicott, J. A. & Johnson, L. N. (1999). The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat Cell Biol 1, 438–443.[CrossRef][Medline]

Carbone, A., Cilia, A. M., Gloghini, A., Capello, D., Todesco, M., Quattrone, S., Volpe, R. & Gaidano, G. (1998). Establishment and characterization of EBV-positive and EBV-negative primary effusion lymphoma cell lines harbouring human herpesvirus type-8. Br J Haematol 102, 1081–1089.[CrossRef][Medline]

Card, G. L., Knowles, P., Laman, H., Jones, N. & McDonald, N. Q. (2000). Crystal structure of a gamma-herpesvirus cyclin–cdk complex. EMBO J 19, 2877–2888.[Abstract/Free Full Text]

Cesarman, E., Chang, Y., Moore, P. S., Said, J. W. & Knowles, D. M. (1995). Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332, 1186–1191.[Abstract/Free Full Text]

Chang, Y., Cesarman, E., Pessin, M. S., Lee, F., Culpepper, J., Knowles, D. M. & Moore, P. S. (1994). Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266, 1865–1869.[Medline]

Chang, Y., Moore, P. S., Talbot, S. J., Boshoff, C. H., Zarkowska, T., Godden, K., Paterson, H., Weiss, R. A. & Mittnacht, S. (1996). Cyclin encoded by KS herpesvirus. Nature 382, 410.[CrossRef][Medline]

Chen, J., Saha, P., Kornbluth, S., Dynlacht, B. D. & Dutta, A. (1996). Cyclin-binding motifs are essential for the function of p21CIP1. Mol Cell Biol 16, 4673–4682.[Abstract]

Cheng, M., Olivier, P., Diehl, J. A., Fero, M., Roussel, M. F., Roberts, J. M. & Sherr, C. J. (1999). The p21Cip1 and p27Kip1 CDK ‘inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18, 1571–1583.[Abstract/Free Full Text]

Child, E. S. & Mann, D. J. (2001). Novel properties of the cyclin encoded by Human Herpesvirus 8 that facilitate exit from quiescence. Oncogene 20, 3311–3322.[CrossRef][Medline]

Ciemerych, M. A., Kenney, A. M., Sicinska, E., Kalaszczynska, I., Bronson, R. T., Rowitch, D. H., Gardner, H. & Sicinski, P. (2002). Development of mice expressing a single D-type cyclin. Genes Dev 16, 3277–3289.[Abstract/Free Full Text]

Clurman, B. E., Sheaff, R. J., Thress, K., Groudine, M. & Roberts, J. M. (1996). Turnover of cyclin E by the ubiquitin–proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 10, 1979–1990.[Abstract]

Clute, P. & Pines, J. (1999). Temporal and spatial control of cyclin B1 destruction in metaphase. Nat Cell Biol 1, 82–87.[CrossRef][Medline]

De Bondt, H. L., Rosenblatt, J., Jancarik, J., Jones, H. D., Morgan, D. O. & Kim, S. H. (1993). Crystal structure of cyclin-dependent kinase 2. Nature 363, 595–602.[CrossRef][Medline]

den Elzen, N. & Pines, J. (2001). Cyclin A is destroyed in prometaphase and can delay chromosome alignment and anaphase. J Cell Biol 153, 121–136.[Abstract/Free Full Text]

Diehl, J. A., Zindy, F. & Sherr, C. J. (1997). Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin–proteasome pathway. Genes Dev 11, 957–972.[Abstract]

Diehl, J. A., Cheng, M., Roussel, M. F. & Sherr, C. J. (1998). Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 12, 3499–3511.[Abstract/Free Full Text]

Djerbi, M., Screpanti, V., Catrina, A. I., Bogen, B., Biberfeld, P. & Grandien, A. (1999). The inhibitor of death receptor signaling, FLICE-inhibitory protein, defines a new class of tumor progression factors. J Exp Med 190, 1025–1032.[Abstract/Free Full Text]

Doxsey, S. J. (2001). Centrosomes as command centres for cellular control. Nat Cell Biol 3, E105–108.[CrossRef][Medline]

Dunaief, J. L., Strober, B. E., Guha, S., Khavari, P. A., Alin, K., Luban, J., Begemann, M., Crabtree, G. R. & Goff, S. P. (1994). The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest. Cell 79, 119–130.[Medline]

Dupin, N., Fisher, C., Kellam, P. & 10 other authors (1999). Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A 96, 4546–4551.[Abstract/Free Full Text]

el-Deiry, W. S., Tokino, T., Velculescu, V. E. & 7 other authors (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817–825.[Medline]

Ellis, M., Chew, Y. P., Fallis, L., Freddersdorf, S., Boshoff, C., Weiss, R. A., Lu, X. & Mittnacht, S. (1999). Degradation of p27Kip cdk inhibitor triggered by Kaposi's sarcoma virus cyclin–cdk6 complex. EMBO J 18, 644–653.[Abstract/Free Full Text]

Endicott, J. A., Noble, M. E. & Tucker, J. A. (1999). Cyclin-dependent kinases: inhibition and substrate recognition. Curr Opin Struct Biol 9, 738–744.[CrossRef][Medline]

Ensoli, B. & Sturzl, M. (1998). Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Cytokine Growth Factor Rev 9, 63–83.[CrossRef][Medline]

Fotedar, R., Fitzgerald, P., Rousselle, T., Cannella, D., Doree, M., Msieser, H. & Fotedar, A. (1996). p21 contains independent binding sites for cyclin and cdk2: both sites are required to inhibit cdk2 kinase activity. Oncogene 12, 2155–2164.[Medline]

Friborg, J., Jr, Kong, W., Hottiger, M. O. & Nabel, G. J. (1999). p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 402, 889–894.[CrossRef][Medline]

Fujimuro, M., Wu, F. Y., ApRhys, C., Kajumbula, H., Young, D. B., Hayward, G. S. & Hayward, S. D. (2003). A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med 9, 300–306.[CrossRef][Medline]

Geley, S., Kramer, E., Gieffers, C., Gannon, J., Peters, J. M. & Hunt, T. (2001). Anaphase-promoting complex/cyclosome-dependent proteolysis of human cyclin A starts at the beginning of mitosis and is not subject to the spindle assembly checkpoint. J Cell Biol 153, 137–148.[Abstract/Free Full Text]

Geng, Y., Yu, Q., Whoriskey, W. & 10 other authors (2001). Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proc Natl Acad Sci U S A 98, 13138–13143.[Abstract/Free Full Text]

Geng, Y., Yu, Q., Sicinska, E. & 7 other authors (2003). Cyclin E ablation in the mouse. Cell 114, 431–443.[Medline]

Gill, P. S., Tsai, Y. C., Rao, A. P., Spruck, C. H., III, Zheng, T., Harrington, W. A., Jr, Cheung, T., Nathwani, B. & Jones, P. A. (1998). Evidence for multiclonality in multicentric Kaposi's sarcoma. Proc Natl Acad Sci U S A 95, 8257–8261.[Abstract/Free Full Text]

Godden-Kent, D., Talbot, S. J., Boshoff, C., Chang, Y., Moore, P., Weiss, R. A. & Mittnacht, S. (1997). The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol 71, 4193–4198.[Abstract]

Gu, Y., Turck, C. W. & Morgan, D. O. (1993). Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366, 707–710.[CrossRef][Medline]

Hagting, A., Jackman, M., Simpson, K. & Pines, J. (1999). Translocation of cyclin B1 to the nucleus at prophase requires a phosphorylation-dependent nuclear import signal. Curr Biol 9, 680–689.[CrossRef][Medline]

Harbour, J. W. & Dean, D. C. (2000). The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 14, 2393–2409.[Free Full Text]

Harbour, J. W., Luo, R. X., Dei Santi, A., Postigo, A. A. & Dean, D. C. (1999). Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98, 859–869.[Medline]

Harper, J. W., Elledge, S. J., Keyomarsi, K. & 9 other authors (1995). Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6, 387–400.[Abstract]

Harper, J. W., Burton, J. L. & Solomon, M. J. (2002). The anaphase-promoting complex: it's not just for mitosis any more. Genes Dev 16, 2179–2206.[Free Full Text]

Helin, K., Harlow, E. & Fattaey, A. (1993). Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol 13, 6501–6508.[Abstract]

Hinchcliffe, E. H. & Sluder, G. (2001). ‘It takes two to tango’: understanding how centrosome duplication is regulated throughout the cell cycle. Genes Dev 15, 1167–1181.[Free Full Text]

Hitomi, M. & Stacey, D. W. (1999). Cyclin D1 production in cycling cells depends on ras in a cell-cycle-specific manner. Curr Biol 9, 1075–1084.[CrossRef][Medline]

Hoge, A. T., Hendrickson, S. B. & Burns, W. H. (2000). Murine gammaherpesvirus 68 cyclin D homologue is required for efficient reactivation from latency. J Virol 74, 7016–7023.[Abstract/Free Full Text]

Ishida, S., Huang, E., Zuzan, H., Spang, R., Leone, G., West, M. & Nevins, J. R. (2001). Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. Mol Cell Biol 21, 4684–4699.[Abstract/Free Full Text]

Jackman, M., Firth, M. & Pines, J. (1995). Human cyclins B1 and B2 are localized to strikingly different structures: B1 to microtubules, B2 primarily to the Golgi apparatus. EMBO J 14, 1646–1654.[Abstract]

Jackman, M., Kubota, Y., den Elzen, N., Hagting, A. & Pines, J. (2002). Cyclin A– and cyclin E–Cdk complexes shuttle between the nucleus and the cytoplasm. Mol Biol Cell 13, 1030–1045.[Abstract/Free Full Text]

Jeffrey, P. D., Russo, A. A., Polyak, K., Gibbs, E., Hurwitz, J., Massague, J. & Pavletich, N. P. (1995). Mechanism of CDK activation revealed by the structure of a cyclinA–CDK2 complex. Nature 376, 313–320.[CrossRef][Medline]

Jeffrey, P. D., Tong, L. & Pavletich, N. P. (2000). Structural basis of inhibition of CDK–cyclin complexes by INK4 inhibitors. Genes Dev 14, 3115–3125.[Abstract/Free Full Text]

Jenner, R. G., Alba, M. M., Boshoff, C. & Kellam, P. (2001). Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays. J Virol 75, 891–902.[Abstract/Free Full Text]

Judde, J. G., Lacoste, V., Briere, J. & 7 other authors (2000). Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. J Natl Cancer Inst 92, 729–736.[Abstract/Free Full Text]

Kaldis, P., Ojala, P. M., Tong, L., Makela, T. P. & Solomon, M. J. (2001). CAK-independent activation of CDK6 by a viral cyclin. Mol Biol Cell 12, 3987–3999.[Abstract/Free Full Text]

Katano, H., Sato, Y. & Sata, T. (2001). Expression of p53 and human herpesvirus-8 (HHV-8)-encoded latency-associated nuclear antigen with inhibition of apoptosis in HHV-8-associated malignancies. Cancer 92, 3076–3084.[CrossRef][Medline]

Kennedy, M. M., O'Leary, J. J., Oates, J. L., Lucas, S. B., Howells, D. D., Picton, S. & McGee, J. O. (1998). Human herpes virus 8 (HHV-8) in Kaposi's sarcoma: lack of association with Bcl-2 and p53 protein expression. Mol Pathol 51, 155–159.[Abstract]

Kim, K. K., Chamberlin, H. M., Morgan, D. O. & Kim, S. H. (1996). Three-dimensional structure of human cyclin H, a positive regulator of the CDK-activating kinase. Nat Struct Biol 3, 849–855.[Medline]

Knudsen, E. S. & Wang, J. Y. (1997). Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 17, 5771–5783.[Abstract]

Kobayashi, H., Stewart, E., Poon, R., Adamczewski, J. P., Gannon, J. & Hunt, T. (1992). Identification of the domains in cyclin A required for binding to, and activation of, p34cdc2 and p32cdk2 protein kinase subunits. Mol Biol Cell 3, 1279–1294.[Abstract]

Kouzarides, T. (1999). Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 9, 40–48.[CrossRef][Medline]

Krek, W., Ewen, M. E., Shirodkar, S., Arany, Z., Kaelin, W. G., Jr & Livingston, D. M. (1994). Negative regulation of the growth-promoting transcription factor E2F-1 by a stably bound cyclin A-dependent protein kinase. Cell 78, 161–172.[Medline]

Kumagai, A. & Dunphy, W. G. (1996). Purification and molecular cloning of Plx1, a Cdc25-regulatory kinase from Xenopus egg extracts. Science 273, 1377–1380.[Abstract]

LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A. & Harlow, E. (1997). New functional activities for the p21 family of CDK inhibitors. Genes Dev 11, 847–862.[Abstract]

Lacoste, V., Mauclere, P., Dubreuil, G., Lewis, J., Georges-Courbot, M. C. & Gessain, A. (2000). KSHV-like herpesviruses in chimps and gorillas. Nature 407, 151–152.[CrossRef][Medline]

Laman, H., Coverley, D., Krude, T., Laskey, R. & Jones, N. (2001). Viral cyclin–cyclin-dependent kinase 6 complexes initiate nuclear DNA replication. Mol Cell Biol 21, 624–635.[Abstract/Free Full Text]

Lees, E. M. & Harlow, E. (1993). Sequences within the conserved cyclin box of human cyclin A are sufficient for binding to and activation of cdc2 kinase. Mol Cell Biol 13, 1194–1201.[Abstract]

Lew, D. J. & Kornbluth, S. (1996). Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol 8, 795–804.[CrossRef][Medline]

Li, M., Lee, H., Yoon, D. W., Albrecht, J. C., Fleckenstein, B., Neipel, F. & Jung, J. U. (1997). Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin. J Virol 71, 1984–1991.[Abstract]

Lin, J., Reichner, C., Wu, X. & Levine, A. J. (1996). Analysis of wild-type and mutant p21WAF-1 gene activities. Mol Cell Biol 16, 1786–1793.[Abstract]

Lukas, J., Herzinger, T., Hansen, K., Moroni, M. C., Resnitzky, D., Helin, K., Reed, S. I. & Bartek, J. (1997). Cyclin E-induced S phase without activation of the pRb/E2F pathway. Genes Dev 11, 1479–1492.[Abstract]

Lukas, C., Sorensen, C. S., Kramer, E., Santoni-Rugiu, E., Lindeneg, C., Peters, J. M., Bartek, J. & Lukas, J. (1999). Accumulation of cyclin B1 requires E2F and cyclin-A-dependent rearrangement of the anaphase-promoting complex. Nature 401, 815–818.[CrossRef][Medline]

Lundberg, A. S. & Weinberg, R. A. (1998). Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin–cdk complexes. Mol Cell Biol 18, 753–761.[Abstract/Free Full Text]

Mann, D. J., Child, E. S., Swanton, C., Laman, H. & Jones, N. (1999). Modulation of p27Kip1 levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. EMBO J 18, 654–663.[Abstract/Free Full Text]

Marti, A., Wirbelauer, C., Scheffner, M. & Krek, W. (1999). Interaction between ubiquitin-protein ligase SCFSKP2 and E2F-1 underlies the regulation of E2F-1 degradation. Nat Cell Biol 1, 14–19.[CrossRef][Medline]

Matsushime, H., Roussel, M. F., Ashmun, R. A. & Sherr, C. J. (1991). Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65, 701–713.[Medline]

Meraldi, P., Honda, R. & Nigg, E. A. (2002). Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53(–/–) cells. EMBO J 21, 483–492.[Abstract/Free Full Text]

Meyerson, M. & Harlow, E. (1994). Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14, 2077–2086.[Abstract]

Montaner, S., Sodhi, A., Pece, S., Mesri, E. A. & Gutkind, J. S. (2001). The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Res 61, 2641–2648.[Abstract/Free Full Text]

Moore, P. S. & Chang, Y. (1998). Antiviral activity of tumor-suppressor pathways: clues from molecular piracy by KSHV. Trends Genet 14, 144–150.[CrossRef][Medline]

Moore, P. S., Gao, S. J., Dominguez, G. & 7 other authors (1996). Primary characterization of a herpesvirus agent associated with Kaposi's sarcomae. J Virol 70, 549–558.[Abstract]

Moore, J. D., Yang, J., Truant, R. & Kornbluth, S. (1999). Nuclear import of Cdk/cyclin complexes: identification of distinct mechanisms for import of Cdk2/cyclin E and Cdc2/cyclin B1. J Cell Biol 144, 213–224.[Abstract/Free Full Text]

Morgan, D. O. (1997). Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol 13, 261–291.[CrossRef][Medline]

Morgan, D. O. (1999). Regulation of the APC and the exit from mitosis. Nat Cell Biol 1, E47–53.[CrossRef][Medline]

Muller, H., Bracken, A. P., Vernell, R. & 7 other authors (2001). E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev 15, 267–285.[Abstract/Free Full Text]

Mundt, K. E., Golsteyn, R. M., Lane, H. A. & Nigg, E. A. (1997). On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression. Biochem Biophys Res Commun 239, 377–385.[CrossRef][Medline]

Nasmyth, K. (2002). Segregating sister genomes: the molecular biology of chromosome separation. Science 297, 559–565.[Abstract/Free Full Text]

Nigg, E. A. (1993). Targets of cyclin-dependent protein kinases. Curr Opin Cell Biol 5, 187–193.[Medline]

Nigg, E. A. (1996). Cyclin-dependent kinase 7: at the cross-roads of transcription, DNA repair and cell cycle control? Curr Opin Cell Biol 8, 312–317.[CrossRef][Medline]

Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M. & Smith, J. R. (1994). Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 211, 90–98.[CrossRef][Medline]

Ohtsubo, M., Theodoras, A. M., Schumacher, J., Roberts, J. M. & Pagano, M. (1995). Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15, 2612–2624.[Abstract]

Ojala, P. M., Tiainen, M., Salven, P., Veikkola, T., Castanos-Velez, E., Sarid, R., Biberfeld, P. & Makela, T. P. (1999). Kaposi's sarcoma-associated herpesvirus-encoded v-cyclin triggers apoptosis in cells with high levels of cyclin-dependent kinase 6. Cancer Res 59, 4984–4989.[Abstract/Free Full Text]

Ojala, P. M., Yamamoto, K., Castanos-Velez, E., Biberfeld, P., Korsmeyer, S. J. & Makela, T. P. (2000). The apoptotic v-cyclin-CDK6 complex phosphorylates and inactivates Bcl-2. Nat Cell Biol 2, 819–825.[CrossRef][Medline]

Ortega, S., Prieto, I., Odajima, J., Martin, A., Dubus, P., Sotillo, R., Barbero, J. L., Malumbres, M. & Barbacid, M. (2003). Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 35, 25–31.[CrossRef][Medline]

Parry, D. H. & O'Farrell, P. H. (2001). The schedule of destruction of three mitotic cyclins can dictate the timing of events during exit from mitosis. Curr Biol 11, 671–683.[CrossRef][Medline]

Paulose-Murphy, M., Ha, N. K., Xiang, C. & 7 other authors (2001). Transcription program of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus). J Virol 75, 4843–4853.[Abstract/Free Full Text]

Pines, J. & Hunter, T. (1991). Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J Cell Biol 115, 1–17.[Abstract]

Poon, R. Y. & Hunter, T. (1995). Dephosphorylation of Cdk2 Thr160 by the cyclin-dependent kinase-interacting phosphatase KAP in the absence of cyclin. Science 270, 90–93.[Abstract]

Qian, Y. W., Erikson, E., Taieb, F. E. & Maller, J. L. (2001). The polo-like kinase Plx1 is required for activation of the phosphatase Cdc25C and cyclin B-Cdc2 in Xenopus oocytes. Mol Biol Cell 12, 1791–1799.[Abstract/Free Full Text]

Radkov, S. A., Kellam, P. & Boshoff, C. (2000). The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma–E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 6, 1121–1127.[CrossRef][Medline]

Ren, B., Cam, H., Takahashi, Y., Volkert, T., Terragni, J., Young, R. A. & Dynlacht, B. D. (2002). E2F integrates cell cycle progression with DNA repair, replication, and G2/M checkpoints. Genes Dev 16, 245–256.[Abstract/Free Full Text]

Rivas, C., Thlick, A. E., Parravicini, C., Moore, P. S. & Chang, Y. (2001). Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol 75, 429–438.[Abstract/Free Full Text]

Russo, A. A., Jeffrey, P. D., Patten, A. K., Massague, J. & Pavletich, N. P. (1996a). Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A–Cdk2 complex. Nature 382, 325–331.[CrossRef][Medline]

Russo, A. A., Jeffrey, P. D. & Pavletich, N. P. (1996b). Structural basis of cyclin-dependent kinase activation by phosphorylation. Nat Struct Biol 3, 696–700.[Medline]

Russo, J. J., Bohenzky, R. A., Chien, M. C. & 8 other authors (1996c). Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci U S A 93, 14862–14867.[Abstract/Free Full Text]

Russo, A. A., Tong, L., Lee, J. O., Jeffrey, P. D. & Pavletich, N. P. (1998). Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a. Nature 395, 237–243.[CrossRef][Medline]

Sarcevic, B., Lilischkis, R. & Sutherland, R. L. (1997). Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin–CDK complexes. J Biol Chem 272, 33327–33337.[Abstract/Free Full Text]

Sarid, R., Olsen, S. J. & Moore, P. S. (1999). Kaposi's sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology. Adv Virus Res 52, 139–232.[Medline]

Schulman, B. A., Lindstrom, D. L. & Harlow, E. (1998). Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. Proc Natl Acad Sci U S A 95, 10453–10458.[Abstract/Free Full Text]

Schulze-Gahmen, U. & Kim, S. H. (2002). Structural basis for CDK6 activation by a virus-encoded cyclin. Nat Struct Biol 9, 177–181.[Medline]

Schulze-Gahmen, U., Jung, J. U. & Kim, S. H. (1999). Crystal structure of a viral cyclin, a positive regulator of cyclin-dependent kinase 6. Structure Fold Des 7, 245–254.[Medline]

Sherr, C. J. (1993). Mammalian G1 cyclins. Cell 73, 1059–1065.[Medline]

Sherr, C. J. (1996). Cancer cell cycles. Science 274, 1672–1677.[Abstract/Free Full Text]

Sherr, C. J. & Roberts, J. M. (1999). CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13, 1501–1512.[Free Full Text]

Sigrist, S., Jacobs, H., Stratmann, R. & Lehner, C. F. (1995). Exit from mitosis is regulated by Drosophila fizzy and the sequential destruction of cyclins A, B and B3. EMBO J 14, 4827–4838.[Abstract]

Singh, P., Coe, J. & Hong, W. (1995). A role for retinoblastoma protein in potentiating transcriptional activation by the glucocorticoid receptor. Nature 374, 562–565.[CrossRef][Medline]

Soulier, J., Grollet, L., Oksenhendler, E. & 7 other authors (1995). Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86, 1276–1280.[Abstract/Free Full Text]

Stewart, Z. A. & Pietenpol, J. A. (2001). p53 signaling and cell cycle checkpoints. Chem Res Toxicol 14, 243–263.[CrossRef][Medline]

Sugimoto, M., Nakamura, T., Ohtani, N. & 8 other authors (1999). Regulation of CDK4 activity by a novel CDK4-binding protein, p34SEI-1. Genes Dev 13, 3027–3033.[Abstract/Free Full Text]

Swanton, C., Mann, D. J., Fleckenstein, B., Neipel, F., Peters, G. & Jones, N. (1997). Herpes viral cyclin/Cdk6 complexes evade inhibition by CDK inhibitor proteins. Nature 390, 184–187.[CrossRef][Medline]

Swanton, C., Card, G. L., Mann, D., McDonald, N. & Jones, N. (1999). Overcoming inhibitions: subversion of CKI function by viral cyclins. Trends Biochem Sci 24, 116–120.[CrossRef][Medline]

Takizawa, C. G. & Morgan, D. O. (2000). Control of mitosis by changes in the subcellular location of cyclin-B1–Cdk1 and Cdc25C. Curr Opin Cell Biol 12, 658–665.[CrossRef][Medline]

Toyoshima, H. & Hunter, T. (1994). p27, a novel inhibitor of G1 cyclin–Cdk protein kinase activity, is related to p21. Cell 78, 67–74.[Medline]

Trimarchi, J. M. & Lees, J. A. (2002). Sibling rivalry in the E2F family. Nat Rev Mol Cell Biol 3, 11–20.[CrossRef][Medline]

van Dyk, L. F., Virgin, H. W. T. & Speck, S. H. (2000). The murine gammaherpesvirus 68 v-cyclin is a critical regulator of reactivation from latency. J Virol 74, 7451–7461.[Abstract/Free Full Text]

Verschuren, E. W., Klefstrom, J., Evan, G. I. & Jones, N. (2002). The oncogenic potential of Kaposi's sarcoma-associated herpesvirus cyclin is exposed by p53 loss in vitro and in vivo. Cancer Cell 2, 229–241.[CrossRef][Medline]

Verschuren, E. W., Hodgson, J. G., Gray, J. W., Kogan, S., Jones, N. & Evan, G. I. (2004). The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res 64, 581–589.[Abstract/Free Full Text]

Visintin, R., Craig, K., Hwang, E. S., Prinz, S., Tyers, M. & Amon, A. (1998). The phosphatase Cdc14 triggers mitotic exit by reversal of Cdk-dependent phosphorylation. Mol Cell 2, 709–718.[Medline]

Vlach, J., Hennecke, S. & Amati, B. (1997). Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 16, 5334–5344.[Abstract/Free Full Text]

Wang, Q., Xie, S., Chen, J., Fukasawa, K., Naik, U., Traganos, F., Darzynkiewicz, Z., Jhanwar-Uniyal, M. & Dai, W. (2002). Cell cycle arrest and apoptosis induced by human polo-like kinase 3 is mediated through perturbation of microtubule integrity. Mol Cell Biol 22, 3450–3459.[Abstract/Free Full Text]

Won, K. A. & Reed, S. I. (1996). Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J 15, 4182–4193.[Abstract]

Wu, L., Timmers, C., Maiti, B. & 12 other authors (2001). The E2F1–3 transcription factors are essential for cellular proliferation. Nature 414, 457–462.[CrossRef][Medline]

Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R. & Beach, D. (1993). p21 is a universal inhibitor of cyclin kinases. Nature 366, 701–704.[CrossRef][Medline]

Yang, J. & Kornbluth, S. (1999). All aboard the cyclin train: subcellular trafficking of cyclins and their CDK partners. Trends Cell Biol 9, 207–210.[CrossRef][Medline]

Yang, R., Morosetti, R. & Koeffler, H. P. (1997). Characterization of a second human cyclin A that is highly expressed in testis and in several leukemic cell lines. Cancer Res 57, 913–920.[Abstract]

Zarkowska, T. U. S., Harlow, E. & Mittnacht, S. (1997). Monoclonal antibodies specific for underphosphorylated retinoblastoma protein identify a cell cycle regulated phosphorylation site targeted by CDKs. Oncogene 14, 249–254.[CrossRef][Medline]

Zhang, H. S., Gavin, M., Dahiya, A., Postigo, A. A., Ma, D., Luo, R. X., Harbour, J. W. & Dean, D. C. (2000). Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC–Rb–hSWI/SNF and Rb–hSWI/SNF. Cell 101, 79–89.[Medline]

Zhong, W., Wang, H., Herndier, B. & Ganem, D. (1996). Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci U S A 93, 6641–6646.[Abstract/Free Full Text]